A Phase 1b study to assess the safety, tolerability, and pharmacodynamics of AZD4144 in participants with established atherosclerotic cardiovascular and chronic kidney disease.

Trial Identifier: D9441C00001
Sponsor: AstraZeneca
Start Date: December 2024
Primary Completion Date: October 2025
Study Completion Date: October 2025
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BG Pleven, BG, 5800
BG Sofia, BG, 1527
HU Gyöngyös, HU, 3200
HU Kistarcsa, HU, 2143
RO Bucharest, RO, 11658
RO Cluj Napoca, RO, 400006
US, CA Glendale, CA, US, 91203
US, FL Daytona Beach, FL, US, 32117
US, FL Jacksonville, FL, US, 32216
US, FL Miami, FL, US, 33125
US, FL Port Orange, FL, US, 32127
US, FL Tampa, FL, US, 33603
US, MI Farmington Hills, MI, US, 48334
US, NY Bronx, NY, US, 10455
US, TX Sherman, TX, US, 75092